 |
Sizzling market heats up biotech buyout fever
December 8, 2009; Fierce Biotech
Biotech buyouts are all the rage these days. Following fast on the heels of yesterday's news that.
more >>
|
Trellis, MedImmune ink antibody deal
December 1, 2009; San Francisco Business Times
Trellis Bioscience Inc. sold a worldwide exclusive license that allows AstraZeneca plc’s MedImmune unit to develop and commercialize antibodies focused on respiratory syncytial virus.
more >>
|
Big Pharma still hungry for biotech deals
November 11, 2009; Reuters
Even amid aggressive cost-cutting, many big pharmaceuticals companies
continue to seek biotech acquisitions in the hope of finding new drugs
to replace those lost to generic competition.
more >>
|
Long, hard road to marketplace for Vanda drug
November 2, 2009; Washington Post
According to a recent report by Dealogic Revenue Analytics, the dollar value of acquisitions by pharmaceutical and biotechnology firms is up 23 percent this year. Across all industries, by comparison, that figure is down 35 percent -- at $1.7 trillion, compared with last year's $2.6 trillion.
more >>
|
Medivation forges $765M cancer deal with Astellas
October 27, 2009; Fierce Biotech
In just the latest sign of just how hot new cancer drugs have become,
San Francisco-based Medivation garnered a $110 million upfront payment
and a milestone package of $655 million from Astellas for global rights
to its experimental prostate cancer drug.
more >>
|
R&D deals drive a spike in M&A activity
October 20, 2009; Fierce Biotech
Easy financing and a hunger for new revenue is driving a record level
of mergers and acquisition in the U.S. healthcare field, and drug
makers and labs are benefiting from the sudden spike.
more >>
|
Biotech industry shows signs of a strong comeback
Thursday, August 13, 2009; Fierce Biotech
The Biotechnology Industry Organization and Thomson Reuters stuck their
fingers into the market air and detected distinct signs of a growing
wind filling the sails of the nation's biotech industry.
more >>
|
Screening Could Lead to More Potent Cancer Drugs
Thursday August 13, 2009; New York Times
Researchers have discovered a way to identify drugs that can specifically attack and kill cancer stem cells.
more >>
|
Bristol-Myers Squibb To Acquire Medarex For $2.1B
Wednesday, July 22, 2009; Wall Street Journal
New York-based Bristol-Myers hopes to expand its portfolio of
biotechnology therapies and specialty drugs, a goal it says Medarex can
help it achieve.
more >>
|
Immune therapies finally working against cancer
Sunday, May 31, 2009; Yahoo! Health
The approach is called a cancer vaccine, although it treats the disease rather than prevents it.
more >>
|
|
|
 -
HEM hematology;
ONCO, oncology;
D&E, Diabetes and endocrinology;
ID*, infectious diseases including HIV;
AIID, Arthritis inflammation and immune disorders;
CNS, central neural system;
GD, genetic disorders;
WH, woman's health.
Others**, respiratory plus cardiovascular;
Source: Datamonitor and company-reported information.
Nature Publishing Group
Nature Biotechnology
|
 |
